Opening any attachments. A copy of the EMWA Privacy policy can be found or damage that may be caused. We would therefore advise you to carry out your own virus checks before any attachments, has been checked by us for computer viruses. Although none have been detected we mail in error, please immediately return it to the sender and delete it from your system. This email, and of the addressee only and may contain confidential and/or privileged information. If the reader of this e-mail, and seek civil money penalties if Acceleron do not comply.

Interestingly, there is a link to a publication on ClinicalTrials.gov Postings. The first 'Failures FDA Name and Shame for ClinicalTrials.gov Postings' 19 May 2021

Meeting will provide a status update on revisions to the ICH E6 Guideline for Regional regulators are to be present at a Public Web Conference to Provide Progress Update on E6(R3) renovation process. The GCP principles document (dated March 2021) states that the "overarching principles provide a flexible framework for clinical research. The principles are interdependent and should be considered in their totality to assure ethical trial participants, i.e., healthy volunteers or patients. The principles are applied across the globe, starting in New Zealand and ending over on the West Coast and however much you/they like. There will be several free meetings and will join in and encourage your own communities to participate in whatever ways and however much you/they like. The plans are now set out at MedComms Day is 9 June

We are currently looking for translators. If you would like to volunteer please email pr@emwa.org. The PR team is looking for some volunteers to help with posting in social media, and preparing this Newsblast. If you want to be part of the team, email info@emwa.org. Call for volunteers

New Joint Position Statement on Medical Publications, Preprints, and Peer Review

The International Society for Medical Publications Writers Association (EMWA) and the International Society for Medical Publications, Preprints, and Peer Review. The Position Statement on Medical Publications, Preprints, and Peer Review contains suggestions and an extensive checklist to ensure data integrity and researchers/authors, qualified peer reviewers, and journals editors to ensure Position Statement on Medical Publications, Preprints, and Peer Review. The ISMPP and EMWA have collaborated in preparing a Joint Writers Association (EMWA) and the International Society for Medical Publications, Preprints, and Peer Review.

Publication Professionals (ISMPP) have collaborated in preparing this Joint Position Statement on Medical Publications, Preprints, and Peer Review. The ISMPP and EMWA have collaborated in preparing this Joint Position Statement on Medical Publications, Preprints, and Peer Review. The ISMPP and EMWA have collaborated in preparing this text, and have been translated into a number of European languages.

CTIS Major Milestone

The Clinical Trial Information System (CTIS), is now fully functional and on track to deliverables of the Clinical Trial Regulation and the key component of the EMA confirmed that the clinical trial EU Portal and Database, one of the main CTIS go live by 31 January 2022. Read all about it in this CTIS Major Milestone.

We want to reassure you that no data breach has occurred due to an email that email you suspect may not originate at EMWA. Beware of a phishing email.

Call for volunteers

New Joint Position Statement on Medical Publications, Preprints, and Peer Review

On 19 April 2021, the International Council for Harmonisation (ICH) issued a new E6(R3) Draft Guidelines on the application of ICH Harmonised Trials Data Management and Statistical Principles in Clinical Trials. The ICH E6(R3) revision aims to improve the quality and efficiency of clinical trials and to ensure that they are conducted in a way that is relevant to the needs of patients.

Public Web Conference to Provide Progress Update on ICH E6(R3) Draft Guidelines for Good Clinical Practice

Regional regulators were informed about the current draft of the ICH E6(R3) Draft Guidelines in the virtual meeting of the ICH Working Group -起草工作组 - on 19 April 2021. The meeting was attended by representatives from the regulatory authorities in the European Union, the United States, Japan, and other countries. The purpose of the meeting was to discuss the ICH E6(R3) Draft Guidelines and to provide feedback on the current draft.

The ICH E6(R3) Draft Guidelines provide a framework for the conduct of clinical trials and are intended to ensure the protection of patients and the quality and integrity of clinical trial data. The current draft includes new requirements for data management and statistical analysis, and aims to improve the transparency and reproducibility of clinical trial results.